CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells

Glioblastoma (GB) remains the most aggressive primary brain malignancy. Adoptive transfer of chimeric antigen receptor (CAR)-modified immune cells has emerged as a promising anti-cancer approach, yet the potential utility of CAR-engineered natural killer (NK) cells to treat GB has not been explored....

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Jianfeng, Chu, Jianhong, Keung Chan, Wing, Zhang, Jianying, Wang, Youwei, Cohen, Justus B., Victor, Aaron, Meisen, Walter H., Kim, Sung-hak, Grandi, Paola, Wang, Qi-En, He, Xiaoming, Nakano, Ichiro, Chiocca, E. Antonio, Glorioso III, Joseph C., Kaur, Balveen, Caligiuri, Michael A., Yu, Jianhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496728/
https://www.ncbi.nlm.nih.gov/pubmed/26155832
http://dx.doi.org/10.1038/srep11483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496728/
https://www.ncbi.nlm.nih.gov/pubmed/26155832
http://dx.doi.org/10.1038/srep11483

Ejemplares similares